This approval is effective from 30 January 2023.
Jubilant Pharmova's wholly owned subsidiary Jubilant Draximage Inc announced that it received approval from the US drug regulator (USFDA) with regards to the company's new drug application (NDA) submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Kit for the Preparation of Technetium (Tc 99m) Mertiatide injection.The Tc 99m Mertiatide injection is used in the diagnosis of congenital and acquired renal abnormalities, renal failure, urinary tract obstruction, and calculi in adults and pediatric patients aged 30 days and older.
The product enables providing renal function, split function, renal angiograms, and renogram curves for whole kidney and renal cortex.
Jubilant Pharmova (formerly Jubilant Life Sciences) is engaged in Radiopharma, Allergy Immunotherapy, CDMO of Sterile Injectable, Generics, Contract Research Development and Manufacturing (CRDMO) and Proprietary Novel Drugs businesses.
With a network of 46 radio-pharmacies in the US, Jubilant's Radiopharma business is engaged in manufacturing and supply of Radiopharmaceutical products and services.
On a consolidated basis, net profit of Jubilant Pharmova declined 96.16% to Rs 5.49 crore on 3% decline in net sales to Rs 1584.74 crore in Q2 September 2022 over Q2 September 2021.
Shares of Jubilant Pharmova jumped 4.50% to Rs 351.95 on Tuesday, 31 January 2023.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
Great minds don’t just skim the surface, they uncover the full story.
You’ve hit your limit of {{free_limit}} free articles this month, subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Months/month
Smart Essential
₹2,700
1 Year
₹225/Months/month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Unlimited access to all articles
30+ premium stories daily, handpicked by our editor


Complimentary Access to The New York Times
News, Games, Cooking, Audio
Wirecutter & The Athletic
Complimentary Access to Our e-Paper
Digital replica of our daily newspaper
Read, save, share any article


Curated Newsletters on Diverse Topics
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Smart Investment Tips
In-depth stock analysis & insights
The Smart Investor for wealth growth tips


Access to Extensive Historical Archives
Repository of articles and publications dating back to 1997
Ad-free Reading Experience
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Repository of articles and publications dating back to 1997